Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study.

[1]  A. Wandinger-Ness,et al.  Progesterone receptor isoform identification and subcellular localization in endometrial cancer. , 2005, Gynecologic oncology.

[2]  Krystal J Alligood,et al.  A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib) , 2004, Cancer Research.

[3]  K. Leslie,et al.  Identification of a novel mechanism of NF-kappaB inactivation by progesterone through progesterone receptors in Hec50co poorly differentiated endometrial cancer cells: induction of A20 and ABIN-2. , 2004, Gynecologic oncology.

[4]  J. Sorosky,et al.  Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. , 2004, Gynecologic oncology.

[5]  T. Herzog.  What is the clinical value of adding tamoxifen to progestins in the treament of advanced or recurrent endometrial cancer , 2004 .

[6]  J. Fiorica,et al.  Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. , 2004, Gynecologic oncology.

[7]  T. Herzog.  What is the clinical value of adding tamoxifen to progestins in the treatment [correction for treament] of advanced or recurrent endometrial cancer? , 2004, Gynecologic Oncology.

[8]  K. Leslie,et al.  Progesterone regulation of activating protein-1 transcriptional activity: a possible mechanism of progesterone inhibition of endometrial cancer cell growth , 2003, The Journal of Steroid Biochemistry and Molecular Biology.

[9]  C. Lange,et al.  MAP kinases couple multiple functions of human progesterone receptors: degradation, transcriptional synergy, and nuclear association , 2003, The Journal of Steroid Biochemistry and Molecular Biology.

[10]  Thomas C Chen,et al.  Combination therapy with irinotecan and protein kinase C inhibitors in malignant glioma , 2003, Cancer.

[11]  K. Horwitz,et al.  Mitogen-activated protein kinase regulates nuclear association of human progesterone receptors. , 2003, Molecular endocrinology.

[12]  C. Burger,et al.  Distinct Functional Differences of Human Progesterone Receptors A and B on Gene Expression and Growth Regulation in Two Endometrial Carcinoma Cell Lines , 2003, The Journal of the Society for Gynecologic Investigation: JSGI.

[13]  J. Fanning,et al.  Immunohistochemical evaluation is not prognostic for recurrence in fully staged high-risk endometrial cancer , 2002, International Journal of Gynecologic Cancer.

[14]  K. Leslie,et al.  Progesterone inhibits human endometrial cancer cell growth and invasiveness: down-regulation of cellular adhesion molecules through progesterone B receptors. , 2002, Cancer research.

[15]  J. Myers,et al.  The Classical Progesterone Receptor Associates with p42 MAPK and Is Involved in Phosphatidylinositol 3-Kinase Signaling inXenopus Oocytes* , 2001, The Journal of Biological Chemistry.

[16]  D. Edwards,et al.  Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases. , 2001, Molecular cell.

[17]  C. Clarke,et al.  Detection of progesterone receptor forms A and B by immunohistochemical analysis , 2001, Journal of clinical pathology.

[18]  M. Dimopoulos,et al.  Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium: long-term results of a phase II multicenter study. , 2000, Gynecologic oncology.

[19]  C. Lange,et al.  Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[20]  R. Alvarez,et al.  Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  T. Iwasaka,et al.  Prognostic significance of progesterone receptor immunohistochemistry for lymph node metastases in endometrial carcinoma. , 1999, Gynecologic oncology.

[22]  T. Iwasaka,et al.  Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma. , 1998, Gynecologic oncology.

[23]  K. Horwitz,et al.  Selective down-regulation of progesterone receptor isoform B in poorly differentiated human endometrial cancer cells: implications for unopposed estrogen action. , 1998, Cancer research.

[24]  G. Greene,et al.  Estrogen receptor immunocytochemistry in endometrial carcinoma: a prognostic marker for survival. , 1996, Gynecologic oncology.

[25]  T. Tamaya,et al.  Expression of progesterone receptor form A and B mRNAs in gynecologic malignant tumors. , 1995, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[26]  B. O’Malley,et al.  Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function. , 1993, Molecular endocrinology.

[27]  H. Norén,et al.  Prognostic value of steroid hormone receptors for 5‐year survival in stage II endometrial cancer , 1993, Cancer.

[28]  W. Creasman.  Prognostic significance of hormone receptors in endometrial cancer , 1993, Cancer.

[29]  E. Milgrom,et al.  Nucleocytoplasmic shuttling of the progesterone receptor. , 1991, The EMBO journal.

[30]  D. Mutch,et al.  Estrogen and progesterone receptor content of endometrial carcinomas: Comparison of total tissue versus cancer component analysis , 1991, Gynecologic Oncology.

[31]  P. Schwartz,et al.  Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Part II: Correlation between biochemical and immunohistochemical methods and survival. , 1990, American journal of clinical pathology.

[32]  C. Clarke,et al.  Progestin regulation of cellular proliferation. , 1990, Endocrine reviews.

[33]  K. McPherson,et al.  Oral contraceptive use influences resting breast proliferation. , 1989, Human pathology.

[34]  S. Ingram,et al.  The predictive value of progesterone receptor levels in endometrial cancer. , 1989, International journal of radiation oncology, biology, physics.

[35]  P. Schwartz,et al.  Estrogen and progestin receptor levels as prognosticators for survival in endometrial cancer. , 1988, Gynecologic oncology.

[36]  G. Sutton,et al.  Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium. , 1988, American journal of obstetrics and gynecology.

[37]  R. Vihko,et al.  Prediction of clinical outcome with estrogen and progestin receptor concentrations and their relationships to clinical and histopathological variables in endometrial cancer. , 1986, Cancer research.

[38]  T. Longacre,et al.  A Correlative Morphologic Study of Human Breast and Endometrium in the Menstrual Cycle , 1986, The American journal of surgical pathology.

[39]  J. Soper,et al.  Histologic control of biochemical steroid receptor analysis in endometrial carcinomas , 1987, American Journal of Obstetrics and Gynecology.

[40]  E B Cox,et al.  Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. , 1985, Archives of pathology & laboratory medicine.

[41]  M. Quinn,et al.  Endometrial carcinoma: steroid receptors and response to medroxyprogesterone acetate. , 1985, Gynecologic oncology.

[42]  K. Mccarty,et al.  Influence of cytoplasmic steroid receptor content on prognosis of early stage endometrial carcinoma. , 1985, American journal of obstetrics and gynecology.

[43]  R. Kurman,et al.  The behavior of endometrial hyperplasia. A long-term study of “untreated” hyperplasia in 170 patients , 1986 .

[44]  P. Satyaswaroop,et al.  Estrogen-like effects of tamoxifen on human endometrial carcinoma transplanted into nude mice. , 1984, Cancer research.

[45]  P. Satyaswaroop,et al.  Heterogeneity and progesterone‐receptor distribution in endometrial adenocarcinoma , 1984, Cancer.

[46]  J. Janssens,et al.  Independent regulation of growth and steroid receptors in uterus and mammary tumors of rats. , 1983, Anticancer Research.

[47]  R. Cleary,et al.  Cytoplasmic progesterone and estradiol receptors in normal, hyperplastic, and carcinomatous endometria: therapeutic implications. , 1981, American journal of obstetrics and gynecology.

[48]  L. Blumenson,et al.  Medroxyprogesterone acetate (depo‐provera) vs. hydroxyprogesterone caproate (Delalutin) in women with metastatic endometrial adenocarcinoma , 1980 .

[49]  T. Benraad,et al.  Do Estrogen and Progesterone Receptors (E2R and PR) in Metastasizing Endometrial Cancers Predict the Response to Gestagen Therapy? , 1980, Acta obstetricia et gynecologica Scandinavica.

[50]  F. Bayard,et al.  Estrogen and progestin regulation of the progesterone receptor concentration in human endometrium. , 1979, The Journal of clinical endocrinology and metabolism.

[51]  K. Mccarty,et al.  Correlation of estrogen and progesterone receptors with histologic differentiation in endometrial adenocarcinoma. , 1979, The American journal of pathology.

[52]  P. Rolland,et al.  Estradiol and progesterone receptors in normal and neoplastic endometrium: Correlations between receptors, histopathological examinations and clinical responses under progestin therapy , 1979, International journal of cancer.

[53]  J. Bonté,et al.  Hormonoprophylaxis and hormonotherapy in the treatment of endometrial adenocarcinoma by means of medroxyprogesterone acetate. , 1978, Gynecologic oncology.

[54]  O. Jänne,et al.  Oestrogen-induced progesterone receptor in human uterus. , 1975, Journal of steroid biochemistry.

[55]  E. C. Reifenstein.  The treatment of advanced endometrial cancer with hydroxyprogesterone caproate. , 1974, Gynecologic oncology.

[56]  R. M. Kelley,et al.  Progestational agents in the treatment of carcinoma of the endometrium. , 1961, The New England journal of medicine.